<DOC>
	<DOCNO>NCT00467987</DOCNO>
	<brief_summary>The purpose study examine effect testosterone deficiency men diabetes atherogenesis , inflammation , cardiovascular Risk factor And adiposity .</brief_summary>
	<brief_title>Effect Androgel Atherogenesis Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism</brief_title>
	<detailed_description>The purpose study examine effect testosterone deficiency men diabetes atherogenesis , inflammation , cardiovascular Risk factor And adiposity . This do comparing change several body response indicator follow treatment testosterone diabetic men low testosterone level compare diabetic men low testosterone treat testosterone . These group also compare diabetic men normal testosterone level</detailed_description>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Males age 3060 year inclusive . PSA &lt; 2.6 ng/ml &lt; 3.75 ng/ml negative prostate biopsy last 6 month . IPSS â‰¤ 19 . The low age limit decide fact study hypogonadotrophic hypogonadism type 2 diabetic patient , young subject 31 year old . The upper age limit restrict 60 avoid include subject significant agerelated decline testosterone concentrations.Subjects thiazolidinediones , statin , ACE inhibitor , angiotensin receptor blocker antioxidant allow long stable dos compound dosage change study . Subjects insulin , metformin sulfonylurea participate study , provide minimal change make dos study Coronary event procedure ( myocardial infarction , unstable angina , coronary artery bypass , surgery coronary angioplasty ) previous four week ; 2 ) Hemoglobin A1c &gt; 10 % ; h/o prostate carcinoma ; Hepatic disease ( transaminase &gt; 3 time normal ) cirrhosis ; Renal impairment ( serum creatinine &gt; 1.5 ) ; HIV Hepatitis C positive status ; Participation concurrent clinical trial ; Any lifethreatening , noncardiac disease ; Use counter health supplement contain androgen ; Use investigational agent therapeutic regimen within 30 day study . Use testosterone past Hematocrit &gt; 50 % .</criteria>
	<gender>Male</gender>
	<minimum_age>31 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>